Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENSER2: Early Norepinephrine in Septic Shock
NCT07343206Recruiting
- Sponsor
- Siriraj Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of norepinephrine in septic shock (2 arms), sponsored by Siriraj Hospital. Primary endpoint: 28-day survival. Started Jan 2026; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT07343206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343206.